Lytix Biopharma have announced the nomination of four new board members.
The four are the Swedish citizens, PhD Marie-Louise Fjällskog and PhD Evelina Vågesjö, the Norwegian citizen Kjetil Hestdal and the US citizen Jayson Rieger. They will all supplement the present board.
Read more: Lytix Biopharma prepares for listing on Euronext Growth Oslo
“I’m very happy that we have been able to nominate four international capacities on cancer treatment. All of them have been key in international successes within commercializing cancer medicines,” says Gert Munthe, chairman of the board.
Evelina Vågesjö, PhD and MBA
Co-founder and CEO of Ilya Pharma AB, a company developing next-generation immunotherapies based on cutting edge medical research in immunophysiology and applied microbiology. Received numerous awards within Science and Innovation, One of the winners of Innovators Under 35 Europe from MIT Technology Review 2019.
“Lytix’s unique science, the major unmet medical needs of patients and the commercial opportunities for the company have all aligned with perfect timing.”
“Lytix’s unique science, the major unmet medical needs of patients and the commercial opportunities for the company have all aligned with perfect timing. If the owners agree, I look forward to working towards the company’s next step of growth together with an international team with diverse demographic and complementary professional experience, i.e. conditions for seeing something really good happen,” says Evelina Vågesjö.
Read more: Interview Evelina Vågesjö: ”I want to see my work go beyond the lab”
Marie-Louise Fjällskog, MD, PhD
Senior Life Science Executive with long track-record within clinical research and business within immunology and oncology. Chief Medical Officer, Sensei Biotherapeutics, Boston, USA Board Member of Biovica International AB, Sweden. Dr. Associate professor (docent) in Oncology, affiliated to Uppsala University.
Kjetil Hestdal, MD, PhD
More than 20 years of entrepreneurship bringing patented products from early stage to launches and commercialization as well as transforming company to R&D to commercial focused company. Has led listed companies with broad international investor relation activities – former CEO of Photocure
Jayson Rieger, PhD and MBA
Jayson Rieger has about 15 years’ experience in cross-functional scientific and business leadership roles spanning business, research operations, drug discovery and product development in the life science. He presently serves as Managing Partner in PBM Capital and supports new investment evaluation, deal sourcing and provides business and technical support for portfolio companies. Jayson obtained his Ph.D. from the University of Virginia in Chemistry, has an MBA from the Darden Business School and earned his B.A. from Rollins College.
Photo of Evelina Vågesjö: Jenny Öhman/Nordic Life Science